Overview Hydroxyzine Hydrochloride (brand name Atarax) is an established pharmaceutical product that has been on the US market since 1956. Originally developed and marketed by Pfizer Inc., the drug is now primarily available as generic versions. The original Atarax products have been withdrawn from the market, though not for safety or effectiveness reasons according to Federal Register determinations. With a total of 1 approved drug in this category, Hydroxyzine Hydrochloride continues to be clinically relevant for several indications including anxiety disorders, urticaria, eczema, and as an antiemetic agent. Detailed Description Drug Information Hydroxyzine Hydrochloride was developed by Pfizer Inc. and first approved in the United States in 1956. All original formulations…
Author: Eileen
Overview The US market has 1 approved drug for trazodone hydrochloride. Trazodone was originally developed by Angelini Pharma, Inc. and first approved in the USA in 1981. It is primarily indicated for major depressive disorder with various formulations including tablets and oral solution. While the original tablets have been withdrawn from the market (though not for safety or effectiveness reasons), a new oral solution formulation was approved in 2024. The drug has a well-established clinical profile with decades of use, and while several patents remain active, most core patents have expired, creating opportunities for generic competition. Detailed Description Drug Information Trazodone Hydrochloride was developed by Angelini Pharma, Inc. and…
[wpforms id=”20204″ title=”false”]
Overview Benzedrex, containing the active ingredient propylhexedrine, is an approved pharmaceutical product primarily indicated for nasal obstruction. The global market for this drug appears to be established, with propylhexedrine having achieved approved status. The drug currently faces minimal patent barriers, as no active core patents were identified in the database, suggesting opportunities for generic manufacturing. Detailed Description Drug Information Propylhexedrine (brand name Benzedrex) is approved for the treatment of nasal obstruction. The drug has reached the “Approved” phase globally, indicating its established presence in pharmaceutical markets. Patent Barrier Analysis Registration Patent Analysis No registration patents were identified for propylhexedrine in the US market. This suggests that the…
Overview Denosumab is an approved biological drug in the U.S. market, with a single reference product developed by Amgen, Inc. As a RANKL inhibitor, Denosumab has received regulatory approval for multiple indications, including osteoporosis, giant cell tumor of bone, and bone metastases. Its clinical significance and commercial potential are underscored by the emergence of 32 biosimilars, such as the Denosumab biosimilar developed by Biocon, reflecting a highly competitive landscape. Drug Information Denosumab received its first U.S. FDA approval on June 1, 2010, and is available in various formulations for indications such as: Biosimilars: There are 32 biosimilars of Denosumab currently…
The US market has 1 approved drug containing Phentermine Hydrochloride/Topiramate (Qsymia), developed by VIVUS, Inc. for the treatment of obesity and overweight conditions. This combination product represents an important option in the weight management pharmaceutical market. Qsymia combines two established active ingredients with different mechanisms of action to provide enhanced weight loss efficacy compared to single-agent therapies. Detailed Description Drug Information Qsymia (Phentermine Hydrochloride/Topiramate) was developed by VIVUS, Inc. and approved in the USA on July 17, 2012. Structure Mechanism of Action Qsymia works through multiple mechanisms including: Patent Statement Information There is 1 patent statement for Qsymia, submitted on July 18, 2013. Registration Patent Barrier Analysis FDA Orange Book patents for Qsymia are held…
Fluence Energy, headquartered in Arlington, Virginia, is a global leader in utility-scale energy storage solutions. Formed as a joint venture between AES Corporation and Siemens, Fluence combines deep energy sector experience with cutting-edge battery and digital intelligence technologies. The company offers modular battery-based systems, software platforms, and service expertise for renewable integration, grid resilience, and energy optimization. This blog unpacks Fluence’s core business model, product lines, innovation strategy, financial performance, and market positioning—using insights from PatSnap Eureka AI Agent. to decode its technological edge. Company Overview FieldDetailsCompany NameFluence Energy, Inc.Founded2017 (JV between AES & Siemens)HeadquartersArlington, Virginia, USAIndustryGrid-scale energy storage and…
Sila Nanotechnologies, headquartered in Alameda, California, is transforming energy storage with its advanced silicon anode materials for lithium-ion batteries. Known for its flagship product, Titan Silicon, Sila delivers higher energy density, faster charging, and safer performance across electric vehicles and consumer electronics. This article explores Sila’s business model, product portfolio, innovation strategy, and market position—supported by insights from PatSnap Eureka AI Agent. Company Overview FieldDetailsCompany NameSila Nanotechnologies, Inc.Founded2011HeadquartersAlameda, California, USAIndustryAdvanced Battery MaterialsKey ExecutivesCEO: Gene Berdichevsky; CTO: Gleb YushinEmployees~200Company TypePrivateBOMTitan Silicon composite, foils, electrolyte binders Organizational Structure Sila operates through integrated teams in materials science, engineering, and manufacturing. The company is…
Solid Power is a Colorado-based energy storage company focused on the development and commercialization of all-solid-state battery technology. Positioned at the intersection of electrification and advanced materials, the company is redefining what’s possible in energy density, safety, and scalability. This article provides a full breakdown of Solid Power’s business model, product portfolio, and innovation strategy—backed by insights from PatSnap Eureka AI Agent. Company Overview FieldDetailsCompany NameSolid Power, Inc.Founded2011HeadquartersLouisville, Colorado, USAWebsitehttps://www.solidpowerbattery.comIndustryAdvanced Energy StorageKey ExecutivesDouglas Campbell (CEO), Derek Johnson (CTO)Employees~165Company TypePublicStock TickerSLDP (NASDAQ)BOMSolid electrolytes, lithium metal anodes, NMC cathodes Organizational Structure Solid Power operates as a vertically integrated entity with dedicated departments…
QuantumScape Corporation is a San Jose, California-based company specializing in the development of solid-state lithium-metal batteries for electric vehicles (EVs). Renowned for its pioneering work on an anode-free cell design and its proprietary “Cobra” separator process, the company is positioning itself as a transformative player in next-generation battery manufacturing. With major partnerships, including Volkswagen, QuantumScape is transitioning from research to pilot-scale production. This blog provides a comprehensive analysis of QuantumScape’s business model, products, IP portfolio, and technology innovation—powered by insights from PatSnap Eureka AI Agent. Company Overview FieldDetailsCompany NameQuantumScape CorporationFounded2010HeadquartersSan Jose, California, USAIndustrySolid-State Batteries for EVKey ExecutivesCEO: Dr. Siva Sivaram;…